Lupin partners with Spanish pharma company Laboratorios ERN on respiratory drug, for Spain

Lupin Limited is partnering with Spanish pharma company Laboratorios ERN SA to launch its fixed dose combination Luforbec (beclometasone/formoterol), in Spain. The drug, administered through a pressurized metered dose inhaler (pMDI), is used to treat adult asthma and chronic obstructive pulmonary disease.

This collaboration combines Lupin’s respiratory expertise and pMDI manufacturing and ERN’s national reach and deep customer relationships, Lupin said. Thierry Volle, Lupin’s President EMEA and Emerging Markets, said, “The launch of Luforbec in Spain, following successful introductions in the UK and Germany, represents a key milestone in our partnership with ERN and reinforces our commitment to advancing global access to quality respiratory care.”

“Partnering with Lupin allows us to bring a proven, high‑value respiratory therapy to Spanish patients and healthcare professionals. It represents an opportunity for ERN to expand into a new therapeutic area,” said David Solanes, Chief Executive of LABORATORIOS ERN, SA.

Published on June 8, 2026